Janice Gabrilove
Affiliations: | Clinical Research | Icahn School of Medicine at Mount Sinai, New York, NY, United States |
Area:
Nursing, Adult and Continuing Education, OncologyGoogle:
"Janice Gabrilove"Children
Sign in to add trainee| Marisa A. Cortese-Peske | grad student | 2013 | Mount Sinai School of Medicine |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Feld J, Tremblay D, Dougherty M, et al. (2021) Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. Hemasphere. 5: e549 |
| Hardy-Abeloos C, Pinotti R, Gabrilove J. (2020) Ibrutinib dose modifications in the management of CLL. Journal of Hematology & Oncology. 13: 66 |
| Thibaud S, Tremblay D, Bhalla S, et al. (2020) Protective Role of BTK Inhibitors in Patients with Chronic Lymphocytic Leukemia and COVID-19. British Journal of Haematology |
| Wang R, Li Y, Gong P, et al. (2018) Arsenic trioxide and sorafenib induce synthetic lethality of FLT3-ITD acute myeloid leukemia cells. Molecular Cancer Therapeutics |
| Brown JR, Harb WA, Hill BT, et al. (2016) Phase 1 study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed or refractory chronic lymphocytic leukemia. Haematologica |
| Prebet T, Sun Z, Ketterling RP, et al. (2015) Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. British Journal of Haematology |
| Lanasa MC, Andritsos L, Brown JR, et al. (2015) Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia Research. 39: 495-500 |
| Zeidan AM, Lee JW, Prebet T, et al. (2014) Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. British Journal of Haematology. 167: 62-8 |
| Zeidan AM, Lee JW, Prebet T, et al. (2014) Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. British Journal of Haematology. 166: 352-9 |
| Prebet T, Sun Z, Figueroa ME, et al. (2014) Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1242-8 |